A Kollár1, R L Jones2, S Stacchiotti3, H Gelderblom4, M Guida5, G Grignani6, N Steeghs7, A Safwat8, D Katz9, F Duffaud10, S Sleijfer11, W T van der Graaf2,12, N Touati13, S Litière13, S Marreaud13, A Gronchi14, B Kasper15. 1. a Sarcoma Unit, Department of Medical Oncology , University Hospital of Bern , Bern , Switzerland. 2. b Sarcoma Unit , Royal Marsden NHS Foundation Trust and Institute of Cancer Research , London , UK. 3. c Sarcoma Unit, Department of Cancer Medicine , Fondazione IRCCS Istituto Nazionale Tumori , Milan , Italy. 4. d Department of Medical Oncology , Leiden University Medical Center , RC Leiden , The Netherlands. 5. e Oncology Department , National Cancer Institute "Giovanni Paolo II" , Bari , Italy. 6. f Division of Medical Oncology , Candiolo Cancer Institue-FPO, IRCCS , Candiolo , Italy. 7. g Department of Medical Oncology , Pharmacology the Netherlands Cancer Institute , Amsterdam , The Netherlands. 8. h Department of Oncology , Aarhus University Hospital , Aarhus , Denmark. 9. i Sharett Institute of Oncology , Hadassah-Hebrew University Medical Center, Kiryat Hadassah , Jerusalem , Israel. 10. j La Timone University Hospital & Aix-Marseille University (AMU) , Marseille , France. 11. k Department of Medical Oncology , Erasmus MC-Cancer Institute, Erasmus University Medical Center , CE Rotterdam , The Netherlands. 12. l Department of Medical Oncology , Radboud University Medical Center , GA Nijmegen , The Netherlands. 13. m European Organization for Research and Treatment of Cancer (EORTC) , Bruxelles , Belgium. 14. n Department of Surgery , Fondazione IRCCS Istituto Nazionale dei Tumori , Milano , Italy. 15. o Sarcoma Unit, Interdisciplinary Tumor Center , Mannheim University Medical Center, University of Heidelberg , Mannheim , Germany.
Abstract
BACKGROUND: Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. PATIENTS AND METHODS: A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed. RESULTS: Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively. CONCLUSION: The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
BACKGROUND:Pazopanibis a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. PATIENTS AND METHODS: A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed. RESULTS: Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively. CONCLUSION: The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Authors: Anna Maria Frezza; Tarek Assi; Salvatore Lo Vullo; Eytan Ben-Ami; Armelle Dufresne; Kan Yonemori; Emi Noguchi; Brittany Siontis; Richard Ferraro; Pawel Teterycz; Florence Duffaud; Vinod Ravi; Bruno Vincenzi; Hans Gelderblom; Maria A Pantaleo; Giacomo G Baldi; Ingrid Desar; Alexander Fedenko; Robert G Maki; Robin L Jones; Robert S Benjamin; Jean Yves Blay; Akira Kawai; Mrinal Gounder; Alessandro Gronchi; Axel Le Cesne; Olivier Mir; Anna M Czarnecka; Scott Schuetze; Andrew J Wagner; Julien Adam; Marta Barisella; Marta Sbaraglia; Jason L Hornick; Alexandra Meurgey; Luigi Mariani; Paolo G Casali; Katherine Thornton; Silvia Stacchiotti Journal: Cancer Date: 2019-09-19 Impact factor: 6.921
Authors: R B Cohen-Hallaleh; H G Smith; R C Smith; G F Stamp; O Al-Muderis; K Thway; A Miah; K Khabra; I Judson; R Jones; C Benson; A J Hayes Journal: Clin Sarcoma Res Date: 2017-08-07